Mitigating Agent for Therapeutic Protein Assay Interference

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting neutralizing antibodies against therapeutic proteins face interference from competing drugs, leading to inaccurate quantitation due to competitive binding to the same drug target.

Innovation Solution

A method involving the use of a mitigating agent to prevent interference from competing drugs in ligand binding assays or cell-based assays, allowing for accurate quantitation of therapeutic proteins by ensuring proper binding to their targets.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a ligand binding assay or cell-based assay is used to detect neutralizing antibodies against therapeutic proteins, then the assay can identify ADA responses, but competing drugs that bind to the same drug target create interference leading to false positive signals and inaccurate quantitation

Engineering Contradiction:

Improveaccuracy of NAb detectionVSAvoidinterference from competing drugs

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a competing drug blocking antibody as an intermediary agent that specifically binds to and blocks the competing drug from interacting with the drug target. This mediator prevents the harmful competitive binding between the competing drug and the therapeutic protein, allowing accurate detection of neutralizing antibodies without false positive signals from drug interference

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary anti-action by pre-incubating the sample with a competing drug blocking antibody before performing the NAb assay. This preliminary step proactively neutralizes the competing drug's ability to bind to the drug target, preventing interference from occurring during the subsequent assay steps and ensuring accurate quantitation of neutralizing antibodies

Inventive Principle:

Principle #9Preliminary anti-action

2Measurement precision

If conventional NAb assays are performed without mitigation of competing drug interference, then the assay procedure remains simple, but the measurement precision of therapeutic protein concentration is compromised

Engineering Contradiction:

Improvequantitation accuracy of therapeutic proteinVSAvoidassay procedure complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent implements preliminary action by incorporating a pre-incubation step where the competing drug blocking antibody is added to the sample before the main NAb assay. This preliminary action prepares the sample by eliminating competing drug interference in advance, ensuring that subsequent measurements of therapeutic protein concentration are precise and accurate without requiring complex mitigation strategies during the assay

Inventive Principle:

Principle #10Preliminary action

3Reliability

If no mitigating agent is added to block competing drug binding, then the assay components and steps remain minimal, but the reliability of diagnostic results is reduced due to false positive NAb signals

Engineering Contradiction:

Improveaccuracy of diagnostic resultsVSAvoidnumber of assay components

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent introduces a competing drug blocking antibody as a targeted intermediary component that specifically addresses the interference from competing drugs. This single well-designed mediator component provides reliable diagnostic results by preventing false positive NAb signals, adding minimal complexity to the assay system while significantly improving result accuracy

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively mitigates interference from competing drugs, enabling accurate detection and quantitation of neutralizing antibodies and therapeutic proteins, thereby improving the reliability of diagnostic assays.

Implementation Method 1

measuring a binding of said therapeutic protein to said target to quantify the concentration of said therapeutic protein

Methodology Applied

Scientific EffectLigand binding:

Implementation Method 2

contacting said sample having a competing drug to (i) said therapeutic protein, (ii) a target of said therapeutic protein, (iii) a detection antibody

Methodology Applied

Scientific EffectImmunoassay binding:

Implementation Method 3

A method involving the use of a mitigating agent to prevent interference from competing drugs in ligand binding assays or cell-based assays

Methodology Applied

Scientific EffectCompetitive binding inhibition:

Data Source

PatentUS20250164501A1Biochemical assays for therapeutic proteins

Publication Date: 2025.05.22 REGENERON PHARMACEUTICALS INC

AI summary

The present invention generally pertains to methods of testing the concentration of therapeutic proteins and testing for the presence of anti-drug antibodies (ADAs) against therapeutic proteins. In particular, the present invention pertains to the use of mitigating agents against interfering competing drugs in ligand binding assays or cell-based assays for the quantification of therapeutic proteins and detection of anti-drug antibodies and neutralizing antibodies against therapeutic proteins.